Last reviewed · How we verify
Calcium polycarbophil
At a glance
| Generic name | Calcium polycarbophil |
|---|---|
| Also known as | Konsyl, Fibercon |
| Sponsor | East Carolina University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- WISH, Feasibility of a Factorial Design (NA)
- Vaginal Dehydroepiandrosterone (DHEA) in Postmenopausal Breast Cancer Survivors on Aromatase Inhibitors (PHASE2)
- Efficacy and Safety of Carboxymethyl Beta-glucan and Policarbophil in HPV Positive Patients
- Randomized Trial of Maternal Progesterone Therapy (PHASE2)
- Sexual Absorption of Vaginal Progesterone (PHASE4)
- Hyaluronic Acid in Counteracting Aphthous Stomatitis
- Efficacy of Intravaginal Carboxymethyl-β-glucan and Polycarbophil on Low-grade Cervical Lesions (GLUCANCIN) (NA)
- Efficacy of an Intravaginal Treatment With Carboxymethyl-β-glucan and Polycarbophil in HR-HPV Clearance (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Calcium polycarbophil CI brief — competitive landscape report
- Calcium polycarbophil updates RSS · CI watch RSS
- East Carolina University portfolio CI